Dr. Sonpavde on long-term outcomes with enfortumab vedotin in urothelial carcinoma

Guru P. Sonpavde, MD, director of the Bladder Cancer Program at Dana-Farber Cancer Institute, and associate professor of Medicine at Harvard Medical School, discusses the 2022 ASCO Annual Meeting abstract, “Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.”